FDA Approves Dupixent for Treatment of Chronic Spontaneous Urticaria
The U.S. Food and Drug Administration has granted approval for Dupixent (dupilumab) to be used in the treatment of adults and adolescents suffering from chronic spontaneous urticaria (CSU). This approval expands the use of Dupixent to include patients aged 12 years and older who continue to experience symptoms despite undergoing treatment with histamine-1 antihistamines.
The decision was supported by results from two phase 3 clinical trials that evaluated the efficacy and safety of Dupixent. These studies involved patients who had not previously received biologic therapy and showed persistent symptoms despite antihistamine treatment. Dupixent was administered as an add-on therapy alongside standard antihistamines and was found to significantly reduce itch severity and urticaria activity over a 24-week period.
In both trials, patients treated with Dupixent were more likely to achieve well-controlled disease or complete symptom relief compared to those receiving placebo. The safety profile observed aligned with what is already established for Dupixent in its other approved indications, indicating a generally well-tolerated treatment.
Alyssa Johnsen, M.D., Ph.D., the global head of immunology and oncology development at Sanofi, emphasized the impact of this approval, stating that uncontrolled CSU can cause profound discomfort and disrupt daily life. She highlighted that Dupixent offers a new therapeutic option targeting the underlying causes of this chronic condition.
This significant development offers hope for patients with challenging CSU symptoms, providing an effective new treatment approach to manage this burdensome skin disorder.
Source: https://medicalxpress.com/news/2025-04-fda-dupixent-chronic-spontaneous-urticaria.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Lung Cancer Trial Model Promises Faster and More Inclusive Research
The Pragmatica-Lung trial demonstrates a fast, inclusive, and efficient model for lung cancer research, providing valuable insights despite not meeting its primary survival endpoint. This approach could revolutionize future clinical trials in oncology.
Harnessing AI and Laboratory Tests to Assess Disease Risks from Rare Genetic Variants
Innovative research combines artificial intelligence with routine laboratory tests to improve prediction of disease risk from rare genetic mutations, enhancing personalized medicine approaches.
Link Between Patient Complaints and Industry Payments to Physicians
A new study highlights the connection between higher patient complaints and increased industry payments to physicians, underscoring the need for better oversight to ensure professional integrity and patient safety.
Back Pain Associated with Increased Risk of Common Chronic Diseases
Research reveals a strong link between chronic back pain and higher rates of serious health conditions like heart disease, arthritis, and diabetes, emphasizing the need for integrated treatment strategies.